-+ 0.00%
-+ 0.00%
-+ 0.00%
On November 18, Kangfang Biotech and Iwasi's overseas partner Summit Therapeutics jointly announced that Kangfang Biotech's global first tumor immunity 2.0 cornerstone drug, evasil contrast valiumab, as a consolidation treatment for locally advanced, unresectable non-small cell lung cancer with no disease progression after receiving radical platinum-containing simultaneous chemoradiotherapy, has begun an international multi-center registration phase III study.
Share
Listen to the news
On November 18, Kangfang Biotech and Iwasi's overseas partner Summit Therapeutics jointly announced that Kangfang Biotech's global first tumor immunity 2.0 cornerstone drug, evasil contrast valiumab, as a consolidation treatment for locally advanced, unresectable non-small cell lung cancer with no disease progression after receiving radical platinum-containing simultaneous chemoradiotherapy, has begun an international multi-center registration phase III study.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending